Disputes and regulatory enforcement

Regulatory enforcement and actions against regulators

The highly regulated nature of the life sciences industry gives rise to the potential for a myriad of regulatory enforcement action for breach of the strict rules governing the sector. Similarly, organisations affected by decisions taken by the regulators responsible for regulating the sector may also wish to take action against those decisions. Regulatory enforcement and action against regulators is possible at both at UK and EU level, depending on the nature of the issue in dispute.

Disputes arising out of the EMA’s approach to transparency

Article 15 of the Treaty on the Functioning of the European Union (TFEU) requires EU institutions, bodies, offices, and agencies to conduct their work as openly as possible and extends the public right of access to documents of all the Union institutions, bodies, offices and agencies. This is often referred to as the principle of transparency. Transparency can be pursued by institutions either by granting access to documents or information upon request (reactive disclosure) or by making documents and information publicly available on their own motion, mainly by publishing it on their websites (proactive disclosure).

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

EU notified bodies propose new medical device governance framework in position paper

The Notified Bodies Coordination Group for Medical Devices (NBCG-Med) and Team-NB Executive Committees has published a position paper proposing reforms to EU medical device governance. The paper recommends the establishment of a Medical Device Coordination Office (MDCO) to address fragmentation and inconsistent implementation in the current regulatory framework.

EFPIA publishes guide on legal and ethical rules for industry-sponsored medical congresses

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has issued a document co-created with the International Pharmaceutical Congress Advisory Association (IPCAA), detailing the legal and ethical standards applicable to industry-sponsored medical congresses in Europe. Published in July 2025, the guide aims to clarify compliance rules for organisations unfamiliar with the EFPIA Code and EU legislation, ensuring consistent standards and transparency across the sector.

Astellas beats generics application to set aside cancer drug patent

Law360: Generic-drug makers on 23 July 2025 failed to convince a London appellate judge to set aside remaining protections for Astellas Pharma's blockbuster prostate cancer treatment, Xtandi, because the evidence provided was 'tainted with hindsight'.

EU AI Act unpacked—guidelines on the scope of obligations for General-Purpose AI models

EU analysis: Theresa Ehlen and Lutz Riede, partners; Laéna Bouafy, senior associate; Verena Kirchmair, associate; Julia Utzerath, senior knowledge lawyer and John-Markus Maddaloni, associate of Freshfields, consider the European Commission’s Guidelines on the scope of obligations for general-purpose AI (GPAI) models, published on 18 July 2025.